Imugene to present at 2024 Cholangiocarcinoma Conference
Filed with ASX · · 3 pages · English
Earlier from Imugene
- Phase 1 onCARlytics Trial Advances to Combination Arm
- Phase 1 onCARlytics Trial Doses First Intravenous Patient
- VAXINIA Phase 1 trial doses patients in higher dose cohorts
- Phase 1 CF33-hNIS Study Update - Positive Early Signals
- Imugene and NeoImmuneTech to Improve Cancer Treatments
Later from Imugene
- Oncolytic Virotherapy CF33 Patent Granted in China
- VAXINIA and HER-Vaxx featured at the AACR Annual Meeting
- Bile Tract Cancer Study Opens after MAST High Dose Clearance
- Imugene and Kincell Bio Announce Strategic Partnership
- Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene